Prostaglandin-associated periorbitopathy in latanoprost users

Código QR

Prostaglandin-associated periorbitopathy in latanoprost users

Shunsuke Nakakura,1 Minamai Yamamoto,1 Etsuko Terao,1 Nozomi Nagatomi,1 Naoko Matsuo,1 Yausko Fujisawa,1 Yuki Fujio,1 Hitoshi Tabuchi,1 Yoshiaki Kiuchi2 1Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan; 2Department of Ophthalmology and Visual Sciences, Graduate School of Bi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nakakura S, Yamamoto M, Terao E, Nagatomi N, Matsuo N, Fujisawa Y, Fujio Y, Tabuchi H, Kiuchi Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/0b319c74ffe14e3ba6c8ea869b4f5e3b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
por: Kanamoto T, et al.
Publicado: (2012)

Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
por: Shimizu Y, et al.
Publicado: (2015)

Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost
por: Maruyama Y, et al.
Publicado: (2015)

The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study
por: Okumichi H, et al.
Publicado: (2017)

Latanoprost in the treatment of glaucoma
por: Alm A
Publicado: (2014)

Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients
por: Michael B Horsley, et al.
Publicado: (2009)

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy
por: Inoue K, et al.
Publicado: (2012)

Prolonged increase in tear meniscus height by 3% diquafosol ophthalmic solution in eyes with contact lenses
por: Nagahara Y, et al.
Publicado: (2015)

Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
por: Pacella F, et al.
Publicado: (2012)

Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration
por: Chavan R, et al.
Publicado: (2014)

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction [Corrigendum]
por: Muñoz Negrete FJ, et al.
Publicado: (2017)

Case of cytomegalovirus retinitis aggravated by sub-Tenon injection of triamcinolone acetonide with subsequent metastatic liver cancer
por: Yamamoto Y, et al.
Publicado: (2013)

Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations
por: Fukuda M, et al.
Publicado: (2013)

Progressive retinal detachment secondary to juxtapapillary microholes in association with type 3 posterior staphylomas
por: Dinah CB, et al.
Publicado: (2014)

Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost
por: Sacchi M, et al.
Publicado: (2014)

24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost
por: Yoshimi Nakamura, et al.
Publicado: (2009)

Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review
por: Andrea Russo, et al.
Publicado: (2009)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost&ndash;timolol, bimatoprost/bimatoprost&ndash;timolol, and travoprost/travoprost&ndash;timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Antoine Lafuma, et al.
Publicado: (2011)

Sequential occlusion of the branch retinal artery and branch retinal vein in a patient with hypertension: an interventional case report
por: Okamoto N, et al.
Publicado: (2014)

Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs
por: Schmier JK, et al.
Publicado: (2014)

Quality of life of glaucoma patients under medical therapy with different prostaglandins
por: Paletta Guedes RA, et al.
Publicado: (2012)

Successful treatment of prostaglandin-induced cystoid macular edema with subtenon triamcinolone
por: Matsuura K, et al.
Publicado: (2012)

Indications and postoperative treatment for Ex-PRESS® insertion in Japanese patients with glaucoma: comparison with standard trabeculectomy
por: Kato N, et al.
Publicado: (2015)

Mirtogenol&reg; potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects
por: Robert D Steigerwalt Jr, et al.
Publicado: (2010)

Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension
por: Lorenz K, et al.
Publicado: (2011)

Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost
por: Hommer A, et al.
Publicado: (2011)

Randomized trial comparing three fixed combinations of prostaglandins/prostamide with timolol maleate
por: Jaime Pablo Kelly Rigollet, et al.
Publicado: (2011)

First-year treatment costs among new initiators of topical prostaglandin analogs
por: Jordana K Schmier, et al.
Publicado: (2009)

Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost
por: Fechtner RD, et al.
Publicado: (2011)

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
por: Gregory Katz, et al.
Publicado: (2010)

Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs
por: Jordana K Schmier, et al.
Publicado: (2010)

Efficacy and tolerability of a large scale change in regimen from latanoprost to travoprost in glaucoma patients at the Manhattan Veterans Administration Hospital
por: Edmund P Farris
Publicado: (2008)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
por: Michael J Miyashiro, et al.
Publicado: (2010)

Efficacy and safety of benzalkonium chloride-free fixed-dose combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension
por: Bhagat P, et al.
Publicado: (2014)

Effect of dorzolamide/timolol combination on the visual field in glaucoma
por: Takeda S, et al.
Publicado: (2014)

Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma
por: Mizoguchi T, et al.
Publicado: (2011)

Effects of brinzolamide vs timolol as an adjunctive medication to latanoprost on circadian intraocular pressure control in primary open-angle glaucoma Japanese patients
por: Makoto Ishikawa, et al.
Publicado: (2009)

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg
por: Yelda Buyru &Ouml;zkurt, et al.
Publicado: (2009)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
por: Myers JS, et al.
Publicado: (2014)

First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results
por: Jordana K Schmier, et al.
Publicado: (2010)